Logo image of PTGX

PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis

NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD

55.22  -0.26 (-0.47%)

After market: 55.22 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PTGX. PTGX was compared to 556 industry peers in the Biotechnology industry. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PTGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

PTGX had positive earnings in the past year.
PTGX had a positive operating cash flow in the past year.
In the past 5 years PTGX reported 4 times negative net income.
In the past 5 years PTGX reported 4 times negative operating cash flow.
PTGX Yearly Net Income VS EBIT VS OCF VS FCFPTGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.57%, PTGX belongs to the top of the industry, outperforming 93.70% of the companies in the same industry.
With an excellent Return On Equity value of 8.16%, PTGX belongs to the best of the industry, outperforming 93.35% of the companies in the same industry.
PTGX has a better Return On Invested Capital (3.04%) than 92.45% of its industry peers.
Industry RankSector Rank
ROA 7.57%
ROE 8.16%
ROIC 3.04%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
PTGX Yearly ROA, ROE, ROICPTGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

PTGX has a better Profit Margin (27.04%) than 96.40% of its industry peers.
The Operating Margin of PTGX (13.10%) is better than 94.42% of its industry peers.
Industry RankSector Rank
OM 13.1%
PM (TTM) 27.04%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTGX Yearly Profit, Operating, Gross MarginsPTGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PTGX is destroying value.
PTGX has more shares outstanding than it did 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PTGX Yearly Shares OutstandingPTGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTGX Yearly Total Debt VS Total AssetsPTGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

PTGX has an Altman-Z score of 39.35. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
PTGX's Altman-Z score of 39.35 is amongst the best of the industry. PTGX outperforms 98.20% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 39.35
ROIC/WACC0.31
WACC9.77%
PTGX Yearly LT Debt VS Equity VS FCFPTGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 17.26 indicates that PTGX has no problem at all paying its short term obligations.
PTGX has a Current ratio of 17.26. This is amongst the best in the industry. PTGX outperforms 90.83% of its industry peers.
A Quick Ratio of 17.26 indicates that PTGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 17.26, PTGX belongs to the top of the industry, outperforming 90.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.26
Quick Ratio 17.26
PTGX Yearly Current Assets VS Current LiabilitesPTGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.26%.
The Revenue for PTGX has decreased by -34.02% in the past year. This is quite bad
PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.
EPS 1Y (TTM)-69.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.83%
Revenue 1Y (TTM)-34.02%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%-88.89%

3.2 Future

Based on estimates for the next years, PTGX will show a decrease in Earnings Per Share. The EPS will decrease by -2.02% on average per year.
Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.60% on average per year.
EPS Next Y-147.2%
EPS Next 2Y-55.79%
EPS Next 3Y-31.85%
EPS Next 5Y-2.02%
Revenue Next Year-74.66%
Revenue Next 2Y-37.72%
Revenue Next 3Y-13.68%
Revenue Next 5Y7.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PTGX Yearly Revenue VS EstimatesPTGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PTGX Yearly EPS VS EstimatesPTGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 73.63, the valuation of PTGX can be described as expensive.
Based on the Price/Earnings ratio, PTGX is valued cheaper than 91.73% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.46. PTGX is valued rather expensively when compared to this.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 73.63
Fwd PE N/A
PTGX Price Earnings VS Forward Price EarningsPTGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaper than 91.73% of the companies in the same industry.
PTGX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTGX is cheaper than 96.94% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.21
EV/EBITDA 78.64
PTGX Per share dataPTGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

A cheap valuation may be justified as PTGX's earnings are expected to decrease with -31.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-55.79%
EPS Next 3Y-31.85%

More info and screens

0

5. Dividend

5.1 Amount

PTGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGONIST THERAPEUTICS INC

NASDAQ:PTGX (7/21/2025, 8:00:01 PM)

After market: 55.22 0 (0%)

55.22

-0.26 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners105.12%
Inst Owner Change0.01%
Ins Owners1.11%
Ins Owner Change0.5%
Market Cap3.42B
Analysts84.71
Price Target70.69 (28.02%)
Short Float %11.19%
Short Ratio7.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)261.96%
Min EPS beat(2)19.4%
Max EPS beat(2)504.52%
EPS beat(4)4
Avg EPS beat(4)138.83%
Min EPS beat(4)12.85%
Max EPS beat(4)504.52%
EPS beat(8)7
Avg EPS beat(8)267.18%
EPS beat(12)10
Avg EPS beat(12)181.66%
EPS beat(16)12
Avg EPS beat(16)136.89%
Revenue beat(2)1
Avg Revenue beat(2)111.72%
Min Revenue beat(2)-8.8%
Max Revenue beat(2)232.24%
Revenue beat(4)2
Avg Revenue beat(4)73.94%
Min Revenue beat(4)-48.93%
Max Revenue beat(4)232.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.43%
PT rev (3m)-0.21%
EPS NQ rev (1m)-1.02%
EPS NQ rev (3m)-2.57%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-10.24%
Revenue NQ rev (1m)13.61%
Revenue NQ rev (3m)14.19%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)-17.73%
Valuation
Industry RankSector Rank
PE 73.63
Fwd PE N/A
P/S 16.47
P/FCF 10.21
P/OCF 10.16
P/B 4.97
P/tB 4.97
EV/EBITDA 78.64
EPS(TTM)0.75
EY1.36%
EPS(NY)-1.79
Fwd EYN/A
FCF(TTM)5.41
FCFY9.8%
OCF(TTM)5.44
OCFY9.84%
SpS3.35
BVpS11.12
TBVpS11.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.57%
ROE 8.16%
ROCE 3.85%
ROIC 3.04%
ROICexc 16.21%
ROICexgc 16.21%
OM 13.1%
PM (TTM) 27.04%
GM N/A
FCFM 161.35%
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 47.82%
Cap/Sales 0.8%
Interest Coverage 250
Cash Conversion 1097.86%
Profit Quality 596.67%
Current Ratio 17.26
Quick Ratio 17.26
Altman-Z 39.35
F-Score5
WACC9.77%
ROIC/WACC0.31
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.83%
EPS Next Y-147.2%
EPS Next 2Y-55.79%
EPS Next 3Y-31.85%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)-34.02%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%-88.89%
Revenue Next Year-74.66%
Revenue Next 2Y-37.72%
Revenue Next 3Y-13.68%
Revenue Next 5Y7.6%
EBIT growth 1Y-81.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-195.56%
EBIT Next 3Y-25.79%
EBIT Next 5YN/A
FCF growth 1Y418.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y421.45%
OCF growth 3YN/A
OCF growth 5YN/A